Celgene (NYSE:CELG) has acquired cancer drug developer Avila Therapeutics in a deal valued up to $925 million if milestones are reached. Avila’s therapeutic platform involves the development of ...

In a sudden management revamp, Celgene President and COO Scott Smith will leave his post at the biotech company, effective immediately. Celgene has recently suffered from a series of major setbacks ...

Flatiron Health, a New York City-based oncology technology company, has expanded its relationships with biotechnology company Celgene Corp. and biopharmaceutical company Amgen. Here are three things ...

Karen Andersen: Investor sentiment on narrow-moat Celgene appears to be at an all-time low, following the failure of a key Crohn's disease drug and FDA approval delays for multiple sclerosis drug ...

Celgene’s shares have dropped nearly 30 percent since October, due to slow sales of its psoriasis drug Otezla, an upcoming patent cliff for its multiple myeloma drug Revlimid, and the failure of an ...

Seattle's NanoString Technologies ($NSTG) stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of ...

Avila Therapeutics Inc., which raised $51 million in venture capital to develop covalent drugs that are designed to silence disease-causing proteins, said it has agreed to be acquired by Celgene Corp.